RT Journal Article
SR Electronic
T1 Direct Comparison of SARS Co-V-2 Nasal RT- PCR and Rapid Antigen Test (BinaxNOW™) at a Community Testing Site During an Omicron Surge
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.08.22268954
DO 10.1101/2022.01.08.22268954
A1 Schrom, John
A1 Marquez, Carina
A1 Pilarowski, Genay
A1 Wang, Grace
A1 Mitchell, Anthea
A1 Puccinelli, Robert
A1 Black, Doug
A1 Rojas, Susana
A1 Riberio, Salu
A1 Martinez, Jacqueline
A1 Jones, Diane
A1 Jain, Vivek
A1 Petersen, Maya
A1 Derisi, Joe
A1 Havlir, Diane
YR 2022
UL http://medrxiv.org/content/early/2022/01/10/2022.01.08.22268954.abstract
AB In 731 persons seeking COVID-19 testing at a walk-up San Francisco community site in January 2022, simultaneous nasal rapid antigen testing (BinaxNOW™) and RT-PCR testing was performed. There were 296 (40.5%) positive tests by RT-PCR; 97% of a random sample were the omicron variant. Sensitivity of a single antigen test was 95.2% (95% CI 92-98%); 82.1% (95% CI 77-87%) and 65.2% (95% CI 60-70%) for Ct threshold of < 30, < 35 and no threshold, respectively. A single BinaxNow™ rapid antigen test detected 95% of high viral load omicron cases from nasal specimens. As currently recommended, repeat testing should be done for high-risk persons with an initial negative antigen test result.Competing Interest StatementDiane Havlir reports non-financial support for other projects from Gilead Sciences and AbbottFunding StatementFunding for this study was provided by UCSF, private donors, the CZ Biohub, and the San Francisco Department of Public Health. The BinaxNOW cards were provided by the California Department of Public Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UCSF Committee on Human Research determined that the study met criteria for public health surveillance. All participants provided informed consent for dual testing.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors